Skip Header

 
Contribute Send feedback
Read comments (1) or add your own

Reviewed, UniProtKB/Swiss-Prot Q99497 (PARK7_HUMAN)

Last modified June 16, 2009. Version 90. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (7) | Third-party data | Customize display text xml rdf/xml gff fasta
Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents

Names and origin

Protein namesRecommended name:
    Protein DJ-1
Alternative name(s):
    Oncogene DJ1
    Parkinson disease protein 7
Gene names
Name: PARK7
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length189 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is not processed.
Protein existenceEvidence at protein level.

General annotation (Comments)

Function

Acts as a positive regulator of androgen receptor-dependent transcription. May function as a redox-sensitive chaperone and as a sensor for oxidative stress. Prevents aggregation of SNCA. Protects neurons against oxidative stress and cell death. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. Ref.1 Ref.9 Ref.12 Ref.16 Ref.18 Ref.23 Ref.25

Subunit structure

Homodimer. Binds EFCAB6/DJBP and PIAS2. Part of a ternary complex containing PARK7, EFCAB6/DJBP and AR. Ref.23 Ref.10 Ref.20 Ref.21 Ref.22 Ref.24

Subcellular location

Nucleus. Cytoplasm. Note: Associated with mitochondria in some cells, particularly after oxidative stress. Detected in tau inclusions in brains from neurodegenerative disease patients. Ref.1 Ref.9 Ref.18 Ref.25 Ref.10 Ref.13 Ref.14 Ref.27

Tissue specificity

Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Ref.1 Ref.13 Ref.14 Ref.15

Induction

By ultraviolet irradiation. Ref.18

Post-translational modification

Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity. Ref.18

Involvement in disease

Defects in PARK7 are the cause of autosomal recessive early-onset Parkinson disease 7 (PARK7) [MIM:606324, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years, slow progression and initial good response to levodopa. Ref.10 Ref.27 Ref.11 Ref.26 Ref.29 Ref.30 Ref.31

Defects in PARK7 influences susceptibility to amyotrophic lateral sclerosis-parkinsonism/dementia complex type 2 [MIM:105500]; also called amyotrophic lateral sclerosis-parkinsonism/dementia complex of Guam or Guam disease. Amyotrophic lateral sclerosis-parkinsonism/dementia complex type 2 is a neurodengenerative disorder with unusually high incidence among the Chamorro people of the Western Pacific Islands of Guam. Both amyotrophic lateral sclerosis and parkinsonism-dementia are chronic, progressive, and uniformly fatal disorders in this population. Both diseases are known to occur in the same kindred, the same sibship, and even the same individual.

Miscellaneous

Cys-106 is easily oxidized to sulfinic acid.

Sequence similarities

Belongs to the peptidase C56 family.

Ontologies

Keywords
   Cellular componentCytoplasm
Nucleus
   Coding sequence diversityPolymorphism
   DiseaseDisease mutation
Parkinson disease
   Molecular functionChaperone
Oncogene
   PTMIsopeptide bond
Oxidation
Phosphoprotein
Ubl conjugation
   Technical term3D-structure
Direct protein sequencing
Gene Ontology (GO)
   Biological processRas protein signal transduction Ref.1

Traceable author statement. Source: ProtInc

   Cellular componentnucleus Ref.1 Ref.27

Inferred from direct assay. Source: MGI

   Molecular functionprotein binding

Inferred from physical interaction. Source: IntAct

Complete GO annotation...

Binary interactions

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Chain1 – 189189Protein DJ-1
PRO_0000157849

Amino acid modifications

Modified residue671Phosphotyrosine Ref.17
Modified residue1061Cysteine sulfinic acid (-SO2H)
Cross-link130Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO) Ref.18

Natural variations

Natural variant261M → I in PARK7; does not affect protein stability and degradation; does not interfere with homodimerization;. Ref.11 Ref.26
VAR_020492
Natural variant641E → D in PARK7; no apparent effect on protein stability. Ref.29 Ref.30
VAR_020493
Natural variant981R → Q Ref.26 Ref.31 Ref.28 Ref.32
VAR_020494
Natural variant1041A → T in PARK7. Ref.31
VAR_020495
Natural variant1491D → A in PARK7. Ref.26
VAR_020496
Natural variant1501G → S Ref.8
VAR_020497
Natural variant1631E → K Ref.33
VAR_034801
Natural variant1661L → P in PARK7; reduces protein stability and leads to increased degradation; interferes with homodimerization; abolishes interaction with PIAS2; strongly reduces chaperone activity. Ref.10 Ref.27 Ref.11 Ref.30
VAR_020498
Natural variant1711A → S Ref.31
VAR_020499

Experimental info

Mutagenesis461C → A: Reduces protein stability. No effect on oxidation. Ref.16 Ref.25
Mutagenesis531C → A: Strongly reduces chaperone activity. Ref.16 Ref.25
Mutagenesis1061C → A or D: Abolishes oxidation and association with mitochondria. No effect on chaperone activity. Ref.16 Ref.25
Mutagenesis1301K → R: Partially compensates for loss of stability; when associated with P-166. Ref.10
Sequence conflict1191F → C in BAB71782. Ref.3

Secondary structure

...................................... 189
Helix Strand Turn

Details...

Sequences

Sequence LengthMass (Da)Tools
Q99497-1 [UniParc].

Last modified July 5, 2004. Version 2.
Checksum: 4B21661B3A76BC67

FASTA18919,891
        10         20         30         40         50         60 
MASKRALVIL AKGAEEMETV IPVDVMRRAG IKVTVAGLAG KDPVQCSRDV VICPDASLED 

        70         80         90        100        110        120 
AKKEGPYDVV VLPGGNLGAQ NLSESAAVKE ILKEQENRKG LIAAICAGPT ALLAHEIGFG 

       130        140        150        160        170        180 
SKVTTHPLAK DKMMNGGHYT YSENRVEKDG LILTSRGPGT SFEFALAIVE ALNGKEVAAQ 


VKAPLVLKD 

« Hide

References

« Hide 'large scale' references
[1]"DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras."
Nagakubo D., Taita T., Kitaura H., Ikeda M., Tamai K., Iguchi-Ariga S.M.M., Ariga H.
Biochem. Biophys. Res. Commun. 231:509-513(1997) [PubMed: 9070310] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY.
Tissue: Cervix carcinoma.
[2]"Homo sapiens RNA-binding protein regulatory subunit mRNA."
Beaudoin R., Hod Y.
Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [MRNA].
Tissue: Lung.
[3]"Human DJ-1 cDNA from PC3 cells."
Ariga H., Niki T.
Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[4]"The DNA sequence and biological annotation of human chromosome 1."
Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K. expand/collapse author list , Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.
Nature 441:315-321(2006) [PubMed: 16710414] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[5]"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
The MGC Project Team
Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
Tissue: Cervix.
[6]"Molecular cloning of human and mouse DJ-1 genes and identification of Sp1-dependent activation of the human DJ-1 promoter."
Taira T., Takahashi K., Kitagawa R., Iguchi-Ariga S.M.M., Ariga H.
Gene 263:285-292(2001) [PubMed: 11223268] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
Tissue: Kidney.
[7]Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.
Submitted (DEC-2008) to UniProtKB
Cited for: PROTEIN SEQUENCE OF 6-27; 33-89; 99-122 AND 149-175, MASS SPECTROMETRY.
Tissue: Brain, Cajal-Retzius cell and Fetal brain cortex.
[8]"DJ-1 gene G150S mutation."
Zou H.Q., Chan P.
Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 138-189, VARIANT SER-150.
[9]"DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor."
Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S.M.M., Ariga H.
J. Biol. Chem. 276:37556-37563(2001) [PubMed: 11477070] [Abstract]
Cited for: INTERACTION WITH PIAS2, SUBCELLULAR LOCATION, FUNCTION.
[10]"L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system."
Miller D.W., Ahmad R., Hague S., Baptista M.J., Canet-Aviles R., McLendon C., Carter D.M., Zhu P.-P., Stadler J., Chandran J., Klinefelter G.R., Blackstone C., Cookson M.R.
J. Biol. Chem. 278:36588-36595(2003) [PubMed: 12851414] [Abstract]
Cited for: DEGRADATION BY THE PROTEASOME, SUBCELLULAR LOCATION, INTERACTION WITH PIAS2, HOMODIMERIZATION, MUTAGENESIS OF LYS-130, CHARACTERIZATION OF VARIANT PARK7 PRO-166.
[11]"A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization."
Moore D.J., Zhang L., Dawson T.M., Dawson V.L.
J. Neurochem. 87:1558-1567(2003) [PubMed: 14713311] [Abstract]
Cited for: DEGRADATION BY THE PROTEASOME, CHARACTERIZATION OF VARIANTS PARK7 ILE-26 AND PRO-166.
[12]"DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex."
Niki T., Takahashi-Niki K., Taira T., Iguchi-Ariga S.M.M., Ariga H.
Mol. Cancer Res. 1:247-261(2003) [PubMed: 12612053] [Abstract]
Cited for: INTERACTION WITH EFCAB6, FUNCTION.
[13]"Immunocytochemical localization of DJ-1 in human male reproductive tissue."
Yoshida K., Sato Y., Yoshiike M., Nozawa S., Ariga H., Iwamoto T.
Mol. Reprod. Dev. 66:391-397(2003) [PubMed: 14579415] [Abstract]
Cited for: TISSUE SPECIFICITY, SUBCELLULAR LOCATION.
[14]"DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia."
Rizzu P., Hinkle D.A., Zhukareva V., Bonifati V., Severijnen L.-A., Martinez D., Ravid R., Kamphorst W., Eberwine J.H., Lee V.M.-Y., Trojanowski J.Q., Heutink P.
Ann. Neurol. 55:113-118(2004) [PubMed: 14705119] [Abstract]
Cited for: TISSUE SPECIFICITY, SUBCELLULAR LOCATION.
[15]"The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease."
Bandopadhyay R., Kingsbury A.E., Cookson M.R., Reid A.R., Evans I.M., Hope A.D., Pittman A.M., Lashley T., Canet-Aviles R., Miller D.W., McLendon C., Strand C., Leonard A.J., Abou-Sleiman P.M., Healy D.G., Ariga H., Wood N.W., de Silva R. expand/collapse author list , Revesz T., Hardy J.A., Lees A.J.
Brain 127:420-430(2004) [PubMed: 14662519] [Abstract]
Cited for: TISSUE SPECIFICITY.
[16]"DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation."
Shendelman S., Jonason A., Martinat C., Leete T., Abeliovich A.
PLoS Biol. 2:1-10(2004) [PubMed: 15502874] [Abstract]
Cited for: FUNCTION, MUTAGENESIS OF CYS-46; CYS-53 AND CYS-106.
[17]"Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."
Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.-M., Polakiewicz R.D., Comb M.J.
Nat. Biotechnol. 23:94-101(2005) [PubMed: 15592455] [Abstract]
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-67, MASS SPECTROMETRY.
[18]"Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities."
Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C., Seino C., Iguchi-Ariga S.M.M., Ariga H.
Cell Death Differ. 13:96-108(2006) [PubMed: 15976810] [Abstract]
Cited for: SUMOYLATION AT LYS-130, OXIDATION, SUBCELLULAR LOCATION, INDUCTION, FUNCTION.
[19]Colinge J., Superti-Furga G., Bennett K.L.
Submitted (OCT-2008) to UniProtKB
Cited for: IDENTIFICATION [LARGE SCALE ANALYSIS], MASS SPECTROMETRY.
[20]"Crystal structure of DJ-1/RS and implication on familial Parkinson's disease."
Huai Q., Sun Y., Wang H., Chin L.-S., Li L., Robinson H., Ke H.
FEBS Lett. 549:171-175(2003) [PubMed: 12914946] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS), HOMODIMERIZATION.
[21]"Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease."
Tao X., Tong L.
J. Biol. Chem. 278:31372-31379(2003) [PubMed: 12761214] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF WILD-TYPE AND MUTANT ARG-130, HOMODIMERIZATION.
[22]"The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease."
Honbou K., Suzuki N.N., Horiuchi M., Niki T., Taira T., Ariga H., Inagaki F.
J. Biol. Chem. 278:31380-31384(2003) [PubMed: 12796482] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS), HOMODIMERIZATION.
[23]"Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain."
Lee S.-J., Kim S.J., Kim I.-K., Ko J., Jeong C.-S., Kim G.-H., Park C., Kang S.-O., Suh P.-G., Lee H.-S., Cha S.-S.
J. Biol. Chem. 278:44552-44559(2003) [PubMed: 12939276] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), FUNCTION, OXIDATION, HOMODIMERIZATION.
[24]"The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease."
Wilson M.A., Collins J.L., Hod Y., Ringe D., Petsko G.A.
Proc. Natl. Acad. Sci. U.S.A. 100:9256-9261(2003) [PubMed: 12855764] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.1 ANGSTROMS), HOMODIMERIZATION, OXIDATION, ABSENCE OF PROTEOLYTIC ACTIVITY.
[25]"The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization."
Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., Cookson M.R.
Proc. Natl. Acad. Sci. U.S.A. 101:9103-9108(2004) [PubMed: 15181200] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS), MUTAGENESIS OF CYS-46; CYS-53 AND CYS-106, OXIDATION, FUNCTION, SUBCELLULAR LOCATION.
[26]"The role of pathogenic DJ-1 mutations in Parkinson's disease."
Abou-Sleiman P.M., Healy D.G., Quinn N., Lees A.J., Wood N.W.
Ann. Neurol. 54:283-286(2003) [PubMed: 12953260] [Abstract]
Cited for: VARIANTS PARK7 ILE-26 AND ALA-149, VARIANT GLN-98.
[27]"Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism."
Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C.J., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P.
Science 299:256-259(2003) [PubMed: 12446870] [Abstract]
Cited for: VARIANT PARK7 PRO-166, SUBCELLULAR LOCATION.
[28]"The R98Q variation in DJ-1 represents a rare polymorphism."
Hedrich K., Schaefer N., Hering R., Hagenah J., Lanthaler A.J., Schwinger E., Kramer P.L., Ozelius L.J., Bressman S.B., Abbruzzese G., Martinelli P., Kostic V., Pramstaller P.P., Vieregge P., Riess O., Klein C.
Ann. Neurol. 55:145-146(2004) [PubMed: 14705128] [Abstract]
Cited for: VARIANT GLN-98.
[29]"Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7)."
Hering R., Strauss K.M., Tao X., Bauer A., Woitalla D., Mietz E.M., Petrovic S., Bauer P., Schaible W., Mueller T., Schoels L., Klein C., Berg D., Meyer P.T., Schulz J.B., Wollnik B., Tong L., Krueger R., Riess O.
Hum. Mutat. 24:321-329(2004) [PubMed: 15365989] [Abstract]
Cited for: VARIANT PARK7 ASP-64, X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
[30]"Differential effects of Parkinson's disease-associated mutations on stability and folding of DJ-1."
Goerner K., Holtorf E., Odoy S., Nuscher B., Yamamoto A., Regula J.T., Beyer K., Haass C., Kahle P.J.
J. Biol. Chem. 279:6943-6951(2004) [PubMed: 14607841] [Abstract]
Cited for: CHARACTERIZATION OF VARIANTS PARK7 ASP-64 AND PRO-166.
[31]"Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations."
Clark L.N., Afridi S., Mejia-Santana H., Harris J., Louis E.D., Cote L.J., Andrews H., Singleton A., Wavrant De-Vrieze F., Hardy J., Mayeux R., Fahn S., Waters C., Ford B., Frucht S., Ottman R., Marder K.
Mov. Disord. 19:796-800(2004) [PubMed: 15254937] [Abstract]
Cited for: VARIANT PARK7 THR-104, VARIANTS GLN-98 AND SER-171.
[32]"DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease."
Hedrich K., Djarmati A., Schafer N., Hering R., Wellenbrock C., Weiss P.H., Hilker R., Vieregge P., Ozelius L.J., Heutink P., Bonifati V., Schwinger E., Lang A.E., Noth J., Bressman S.B., Pramstaller P.P., Riess O., Klein C.
Neurology 62:389-394(2004) [PubMed: 14872018] [Abstract]
Cited for: VARIANT GLN-98.
[33]"DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex."
Annesi G., Savettieri G., Pugliese P., D'Amelio M., Tarantino P., Ragonese P., La Bella V., Piccoli T., Civitelli D., Annesi F., Fierro B., Piccoli F., Arabia G., Caracciolo M., Ciro Candiano I.C., Quattrone A.
Ann. Neurol. 58:803-807(2005) [PubMed: 16240358] [Abstract]
Cited for: VARIANT LYS-163.
+Additional computationally mapped references.

Web resources

GeneReviews
SHMPD

The Singapore human mutation and polymorphism database

Cross-references

Sequence databases

D61380 mRNA. Translation: BAA09603.2.
AF021819 mRNA. Translation: AAC12806.1.
AB073864 mRNA. Translation: BAB71782.1.
AL034417 Genomic DNA. Translation: CAB52550.1.
BC008188 mRNA. Translation: AAH08188.1.
AB045294 Genomic DNA. No translation available.
AY648999 Genomic DNA. Translation: AAT68961.1.
IPIIPI00298547.
PIRJC5394.
RefSeqNP_001116849.1.
NP_009193.2.
UniGeneHs.419640

3D structure databases

EntryMethodResolution (Å)ChainPositionsPDBsum
1J42X-ray2.50A1-189[»]
1P5FX-ray1.10A1-189[»]
1PDVX-ray1.80A1-189[»]
1PDWX-ray2.20A/B/C/D/E/F/G/H1-189[»]
1PE0X-ray1.70A/B1-189[»]
1PS4X-ray1.60A1-189[»]
1Q2UX-ray1.60A1-189[»]
1SOAX-ray1.20A1-189[»]
1UCFX-ray1.95A/B1-189[»]
2OR3X-ray1.20A/B1-189[»]
2R1TX-ray1.70A2-188[»]
B2-188[»]
2R1UX-ray1.50A/B2-188[»]
2R1VX-ray1.70A2-188[»]
B2-188[»]
2RK3X-ray1.05A1-189[»]
2RK4X-ray1.15A1-189[»]
2RK6X-ray1.15A1-189[»]
3B36X-ray1.50A1-189[»]
3B38X-ray1.85A1-189[»]
3B3AX-ray1.50A1-189[»]
3BWEX-ray2.40A/B/C/D/E/F/G1-189[»]
3CY6X-ray1.35A1-189[»]
3CYFX-ray1.60A1-189[»]
3CZ9X-ray1.15A1-189[»]
3CZAX-ray1.20A1-189[»]
3EZGX-ray1.15A1-189[»]
3F71X-ray1.20A1-189[»]
ModBaseSearch...

Protein-protein interaction databases

IntActQ99497. 10 interactions.

Protein family/group databases

MEROPSC56.002.

PTM databases

PhosphoSiteQ99497.

2-D gel databases

Cornea-2DPAGEQ99497.
OGPQ99497.
REPRODUCTION-2DPAGEIPI00298547.

Proteomic databases

PeptideAtlasQ99497.
PRIDEQ99497.

Genome annotation databases

EnsemblENSG00000116288. Homo sapiens. [Contig view]
GeneID11315.
KEGGhsa:11315.

Organism-specific databases

GeneCardsGC01P007944.
H-InvDBHIX0000097.
HGNCHGNC:16369. PARK7.
HPACAB005870.
HPA004190.
MIM105500. phenotype.
168600. phenotype.
602533. gene.
606324. phenotype.
Orphanet2828. Parkinson disease, genetic types.
PharmGKBPA32946.
GenAtlasSearch...

Phylogenomic databases

HOGENOMQ99497.
HOVERGENQ99497.
OMAQ99497. GDHYKYS.

Enzyme and pathway databases

Pathway_Interaction_DBalphasynuclein_pathway. Alpha-synuclein signaling.

Gene expression databases

ArrayExpressQ99497.
BgeeQ99497.
CleanExHS_PARK7.

Family and domain databases

InterProIPR006287. DJ1.
IPR002818. ThiJ/PfpI.
[Graphical view]
PfamPF01965. DJ-1_PfpI. 1 hit.
[Graphical view]
TIGRFAMsTIGR01383. not_thiJ. 1 hit.
ProtoNetSearch...

Other Resources

NextBio42983.
PMAP-CutDBQ99497.
SOURCESearch...

Entry information

Entry namePARK7_HUMAN
AccessionPrimary (citable) accession number: Q99497
Secondary accession number(s): O14805, Q6DR95, Q7LFU2
Entry history
Integrated into UniProtKB/Swiss-Prot: December 7, 2004
Last sequence update: July 5, 2004
Last modified: June 16, 2009
This is version 90 of the entry and version 2 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation projectHPI (Human Proteome Initiative)

Relevant documents

Human chromosome 1

Human chromosome 1: entries, gene names and cross-references to MIM

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

PDB cross-references

Index of Protein Data Bank (PDB) cross-references

Peptidase families

Classification of peptidase families and list of entries

SIMILARITY comments

Index of protein domains and families

Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents